Navigation Links
Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
Date:11/4/2011

or JX-594 in Liver Cancer

Data from two Phase 2 clinical trials using JX-594 to treat liver cancer were announced earlier this year. In the first trial, preliminary data from 30 patients indicated that the risk of death for patients who received JX-594 at the high therapeutic dose was markedly reduced by more than 50 percent (hazard ratio <0.5) when compared to patients randomized to a control low dose (one-tenth of the high dose).  

In a second Phase 2 trial which sequentially combined intravenous and intratumoral administration of JX-594 and sorafenib treatment, interim data from 15 patients, including a subgroup of 10 who have failed previous treatment with sorafenib, demonstrated tumor responses by Choi criteria (a measure of tumor necrosis) in both injected and non-injected tumors in eight of 11 evaluable patients. Tumor responses were maintained for up to 15 months post JX-594 treatment initiation. Significant tumor necrosis following JX-594 and sorafenib was observed in six of seven evaluable sorafenib resistant patients (86 percent).

Hepatocellular Carcinoma: A Global Unmet Need

Hepatocellular carcinoma is the fifth most common cancer worldwide and the third leading cause of cancer death, with over 600,000 new cases diagnosed annually resulting in more than 90 percent mortality.  The annual incidence rate in the U.S., Europe, Japan and China are estimated to be 20,000, 55,000, 40,000 and 350,000 patients, respectively.  Currently, there is only one approved agent for HCC, a drug called sorafenib (Nexavar®), which is associated with moderate efficacy (tumor response rate of <5%) and a side effect profile that has resulted in discontinuation of use in some patients.

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer t
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic ... complete healing of an otherwise non-healing surgical knee wound. , The case involved ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... for venture capital funds, investment firms and animal health companies to hear from ... raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... Mich. , Aug. 27, 2015  Neogen Corporation ... acquired the stock of United Kingdom ... of microbiological culture media and diagnostic systems. ... grown into a leading provider of microbial testing and ... clinical testing markets. The company currently sells into more ...
(Date:8/27/2015)... Fla. , Aug. 27, 2015 The ... that a patient,s eyes—and life—were saved by doctors at ... , working with NNFF, NovaBay Pharmaceuticals and Dr. ... Care Center at Seton Medical Center in ... successful treatment used a breakthrough approach, pioneered by Dr. ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... With the Middle Class Using India,s Private Health Care ... be an Increasing Need for Diagnostic Imaging ... Group,forecasts that growing demand for private health care in ... As a result, the,market will experience rapid growth, reaching ...
... can be Used to Accurately Measure Cardiac Output ... During Cardiopulmonary Exercise Testing (CPX), WASHINGTON, September 19 ... real-time,cardiac output monitoring, announced at HFSA the results of the ... peak,exercise." The study, led by Dr. Jon Myers of ...
... Surgical,Corp. today announced that it has filed a registration statement ... to a proposed,initial public offering of its common stock. ... Surgical Corp. The,number of shares to be offered and the ... Company intends to apply to have its common stock,approved for ...
Cached Biology Technology:Not Just for the Rich: India's Private Health Care is Booming 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 3MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, Inc ... improving the user experience and security of consumer ... today announced that its TrulySecure™ is ... software to be FIDO Certified™. The ... compliance with the FIDO UAF (Universal Authentication Framework) ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
... is steering a very unsustainable course when it comes ... engineer and researcher, Izzo is chairman, president and chief ... In the first Technology and Society Forum ... how the impacts of climate change and an uncertain ...
... from the U.S. National Science Foundation and the U.S. ... marked the occasion of the research vessel JOIDES Resolution ... transit to Honolulu, after a complete transformation to modernize ... The JOIDES Resolution is the U.S. research vessel ...
... scan of millions of genetic mutations has revealed four new ... group of researchers led by the University of Michigan and ... has shown in a just-published study. Appearing Jan. ... confirmed that two other previously identified DNA sites, discovered by ...
Cached Biology News:PSEG's Ralph Izzo to explore at NJIT the impacts of climate change, more 2Ocean research officials hail completion of modernization for US scientific ocean drilling vessel 2Researchers identify 4 genetic hotspots associated with psoriasis 2Researchers identify 4 genetic hotspots associated with psoriasis 3
... The dotLab System brings together ... diffraction and immobilized capture surfaces. This ... simple technique for the detection of ... of fluorescent labels. , Protein-specific capture ...
... RY 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: ... ethanol precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), ... X-100, 0.01% BSA, 50% glycerol. Shipping and Storage: ... Definition: One unit is defined as the amount ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
... experiment based analysis package designed with easy ... and powerful functionality., Image acquisition interface is ... easy image capture. Sequential and dynamic ... Saturation Warning Single ...
Biology Products: